GlassScriptPhysician profile
Minh H Nguyen
NPI 1750695839
$17,077.45
in general payments reported to CMS, 2019-2025
51 companies · $3,162 in 2025
The $3,162 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,323 · 2020: $2,115 · 2021: $2,247 · 2022: $2,020 · 2023: $2,436 · 2024: $2,774 · 2025: $3,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,351 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,351.47 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,382.41 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $2,126.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,450.07 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,423.29 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,222.50 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,168.12 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $990.39 | 2019-2025 | |
| Abbvie INC. | $953.50 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $580.58 | 2019-2025 | Xarelto, Spravato |
| Sanofi-Aventis U.S. LLC | $467.72 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $431.85 | 2020-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.56 | 2020-2024 | Xifaxan |
| Exact Sciences Corporation | $327.86 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $305.97 | 2019-2025 | Eliquis, Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $281.09 | 2019-2025 | Trintellix |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minh Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.